Ruxolitinib
CAS 941678-49-5
Ruxolitinib (CAS 941678-49-5) is a pharmaceutical compound with 80 bioactivity targets and 480 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
141
SOURCE
DrugCentral
Adverse signals
480
SOURCE
IUPHAR/BPS
PubMed IDs
3
SOURCE
DrugCentral
055904D152D6
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Ruxolitinib
CAS Number
941678-49-5
UNII
82S8X8XX8H
InChIKey
HFNKQEVNSGCOJV-OAHLLOKOSA-N
ChEMBL ID
CHEMBL1789941
DrugCentral Struct ID
4190
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
SOURCE
EMBL-EBI ChEMBL
80 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Rho-associated protein kinase 2 Kinase |
Kd | 7.28 | - | Homo sapiens |
| Tyrosine-protein kinase JAK3 Kinase |
Kd | 8.7 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 5.96 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 5.2 | - | Homo sapiens |
| Serine/threonine-protein kinase B-raf Kinase |
Kd | 5.66 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase receptor Ret Kinase |
Kd | 6.72 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase |
Kd | 6 | - | Homo sapiens |
| Myosin light chain kinase, smooth muscle Kinase |
Kd | 6.44 | - | Homo sapiens |
| Death-associated protein kinase 3 Kinase |
Kd | 7.05 | - | Homo sapiens |
| Histone deacetylase 6 Enzyme |
IC50 | 7.82 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type 1 Kinase |
Kd | 6.33 | - | Homo sapiens |
| Mitogen-activated protein kinase 8 Kinase |
Kd | 5.32 | - | Homo sapiens |
| Rho-associated protein kinase 1 Kinase |
Kd | 7.22 | - | Homo sapiens |
| Tyrosine-protein kinase JAK1 Kinase |
Ki | 10.05 | - | Homo sapiens |
| Serine/threonine-protein kinase PLK1 Kinase |
Kd | 6.89 | - | Homo sapiens |
| Death-associated protein kinase 2 Kinase |
Kd | 7.01 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 5.82 | - | Homo sapiens |
| Tyrosine-protein kinase JAK2 Kinase |
Kd | 10.44 | - | Homo sapiens |
| Protein kinase C alpha type Kinase |
Kd | 4.78 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase |
Kd | 7.05 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase |
Kd | 7 | - | Homo sapiens |
| AP2-associated protein kinase 1 Kinase |
Kd | 6.92 | - | Homo sapiens |
| Serine/threonine-protein kinase MARK2 Kinase |
Kd | 6.18 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-2 Kinase |
Kd | 6.82 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase |
Kd | 6.51 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase |
Kd | 5.24 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase |
Kd | 7.34 | - | Homo sapiens |
| Serine/threonine-protein kinase 17B Kinase |
Kd | 5.46 | - | Homo sapiens |
| Protein kinase C epsilon type Kinase |
Kd | 6.28 | - | Homo sapiens |
| Serine/threonine-protein kinase PLK4 Kinase |
Kd | 6.7 | - | Homo sapiens |
| Aurora kinase C Kinase |
Kd | 5.06 | - | Homo sapiens |
| Serine/threonine-protein kinase 16 Kinase |
Kd | 6.31 | - | Homo sapiens |
| Dual specificity protein kinase TTK Kinase |
Kd | 6.32 | - | Homo sapiens |
| Serine/threonine-protein kinase N1 Kinase |
Kd | 5.52 | - | Homo sapiens |
| Serine/threonine-protein kinase 17A Kinase |
Kd | 5.21 | - | Homo sapiens |
| ALK tyrosine kinase receptor Kinase |
Kd | 5.82 | - | Homo sapiens |
| Ephrin type-A receptor 3 Kinase |
Kd | 5.21 | - | Homo sapiens |
| BMP-2-inducible protein kinase Kinase |
Kd | 6.68 | - | Homo sapiens |
| Dual specificity protein kinase CLK1 Kinase |
Kd | 5.49 | - | Homo sapiens |
| Dual specificity protein kinase CLK2 Kinase |
Kd | 6.34 | - | Homo sapiens |
| Cyclin-G-associated kinase Kinase |
Kd | 7 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type 1D Kinase |
Kd | 6.92 | - | Homo sapiens |
| Activated CDC42 kinase 1 Kinase |
Kd | 5.59 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-5 Kinase |
Kd | 6.85 | - | Homo sapiens |
| Dual specificity protein kinase CLK4 Kinase |
Kd | 5.77 | - | Homo sapiens |
| MAP kinase-interacting serine/threonine-protein kinase 2 Kinase |
Kd | 6.7 | - | Homo sapiens |
| MAP/microtubule affinity-regulating kinase 3 Kinase |
Kd | 4.83 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type 1G Kinase |
Kd | 5.66 | - | Homo sapiens |
| Inhibitor of nuclear factor kappa-B kinase subunit beta Kinase |
Kd | 5.64 | - | Homo sapiens |
| Dual specificity mitogen-activated protein kinase kinase 1 Kinase |
Kd | 5.72 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Splenomegaly | 872 | 2294.153 | 10041660 |
| Platelet count decreased | 1388 | 1520.768 | 10035528 |
| Anaemia | 2016 | 1467.839 | 10002034 |
| Haemoglobin decreased | 1341 | 1298.195 | 10018884 |
| Second primary malignancy | 504 | 1256.096 | 10039801 |
| Platelet count increased | 546 | 1170.028 | 10051608 |
| Death | 2053 | 905.324 | 10011906 |
| White blood cell count increased | 646 | 814.538 | 10047943 |
| Product use in unapproved indication | 1087 | 678.323 | 10076476 |
| Thrombocytopenia | 1015 | 590.929 | 10043554 |
| Acute myeloid leukaemia | 358 | 533.431 | 10000880 |
| Full blood count abnormal | 360 | 441.514 | 10017412 |
| Myelofibrosis | 158 | 440.511 | 10028537 |
| Product availability issue | 168 | 399.152 | 10077800 |
| Blast cell count increased | 118 | 393.556 | 10062274 |
| Red blood cell count decreased | 360 | 353.169 | 10038153 |
| Transformation to acute myeloid leukaemia | 96 | 330.01 | 10079107 |
| Product dose omission issue | 809 | 302.732 | 10084406 |
| Squamous cell carcinoma | 198 | 297.831 | 10041823 |
| Off label use | 1885 | 279.323 | 10053762 |
| Infusion related reaction | 4 | 262.616 | 10051792 |
| Leukaemia | 136 | 256.962 | 10024288 |
| Cytopenia | 199 | 249.312 | 10066274 |
| Platelet count abnormal | 118 | 240.278 | 10035526 |
| Drug hypersensitivity | 31 | 239.622 | 10013700 |
| Graft versus host disease in gastrointestinal tract | 118 | 225.303 | 10075160 |
| Rheumatoid arthritis | 9 | 224.296 | 10039073 |
| Blood lactate dehydrogenase increased | 233 | 221.301 | 10005630 |
| Haematocrit decreased | 278 | 210.506 | 10018838 |
| Iron overload | 81 | 208.651 | 10065973 |
| Graft versus host disease in skin | 108 | 204.038 | 10064675 |
| Leukocytosis | 224 | 193.775 | 10024378 |
| Graft versus host disease in liver | 71 | 187.493 | 10064676 |
| Haematocrit increased | 89 | 186.995 | 10018840 |
| Systemic lupus erythematosus | 3 | 183.511 | 10042945 |
| Acute leukaemia | 73 | 182.004 | 10000830 |
| Thrombocytosis | 112 | 180.045 | 10043563 |
| Completed suicide | 6 | 176.674 | 10010144 |
| Febrile neutropenia | 559 | 174.167 | 10016288 |
| Early satiety | 66 | 174.033 | 10059186 |
| Cytomegalovirus infection reactivation | 107 | 172.406 | 10058666 |
| Maternal exposure during pregnancy | 8 | 169.318 | 10071408 |
| Arthropathy | 21 | 166.25 | 10003285 |
| Concomitant disease aggravated | 121 | 165.545 | 10010253 |
| Night sweats | 242 | 163.785 | 10029410 |
| Synovitis | 5 | 160.354 | 10042868 |
| Contusion | 436 | 157.669 | 10050584 |
| Therapeutic product effect decreased | 13 | 156.966 | 10082201 |
| Myeloproliferative neoplasm | 54 | 150.035 | 10077465 |
| Pneumonia | 1190 | 147.59 | 10035664 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
8 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Janus kinase 1 JAK1 |
Inhibition | 8.220000267028809 pIC50 | 24417533 |
| Janus kinase 1 JAK1 |
Inhibition | 8.479999542236328 pIC50 | 20130243|23061660 |
| Janus kinase 2 JAK2 |
Inhibition | 8.050000190734863 pIC50 | 24417533 |
| Janus kinase 2 JAK2 |
Inhibition | 8.550000190734863 pIC50 | 20130243|23061660 |
| Janus kinase 3 JAK3 |
Inhibition | 8.489999771118164 pIC50 | 23061660 |
| Janus kinase 3 JAK3 |
Inhibition | 6.309999942779541 pIC50 | 24417533 |
| tyrosine kinase 2 TYK2 |
Inhibition | 7.519999980926514 pIC50 | 24417533 |
| tyrosine kinase 2 TYK2 |
Inhibition | 9.260000228881836 pIC50 | 23061660 |
SOURCE
NLM RxNorm
2 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| RUXOLITINIB | 1193326 | SU | MTHSPL |
| ruxolitinib | 1193326 | IN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Alanine aminotransferase increased | ruxolitinib | LLT | C0151905 |
| Alanine aminotransferase increased | ruxolitinib | PT | C0151905 |
| Anaemia | ruxolitinib | LLT | C0002871 |
| Anaemia | ruxolitinib | PT | C0002871 |
| Asthenia | ruxolitinib | PT | C0004093 |
| Blood and lymphatic system disorders | ruxolitinib | - | C0851353 |
| Blood pressure systolic increased | ruxolitinib | LLT | C0277884 |
| Blood pressure systolic increased | ruxolitinib | PT | C0277884 |
| Body temperature increased | ruxolitinib | LLT | C0015967 |
| Body temperature increased | ruxolitinib | PT | C0015967 |
| Bone pain | ruxolitinib | LLT | C0151825 |
| Bone pain | ruxolitinib | PT | C0151825 |
| Contusion | ruxolitinib | LLT | C0009938 |
| Contusion | ruxolitinib | PT | C0009938 |
| Dizziness | ruxolitinib | LLT | C0012833 |
| Dizziness | ruxolitinib | PT | C0012833 |
| Epistaxis | ruxolitinib | LLT | C0014591 |
| Epistaxis | ruxolitinib | PT | C0014591 |
| Fatigue | ruxolitinib | LLT | C0015672 |
| Fatigue | ruxolitinib | PT | C0015672 |
| Flatulence | ruxolitinib | LLT | C0016204 |
| Flatulence | ruxolitinib | PT | C0016204 |
| Gastrointestinal disorder | ruxolitinib | LLT | C0017178 |
| Gastrointestinal disorder | ruxolitinib | PT | C0017178 |
| Gastrointestinal haemorrhage | ruxolitinib | LLT | C0017181 |
| Gastrointestinal haemorrhage | ruxolitinib | PT | C0017181 |
| Haematuria | ruxolitinib | LLT | C0018965 |
| Haematuria | ruxolitinib | PT | C0018965 |
| Haemoglobin | ruxolitinib | PT | C0518015 |
| Haemorrhage | ruxolitinib | LLT | C0019080 |
| Haemorrhage | ruxolitinib | PT | C0019080 |
| Haemorrhage intracranial | ruxolitinib | LLT | C0151699 |
| Haemorrhage intracranial | ruxolitinib | PT | C0151699 |
| Headache | ruxolitinib | LLT | C0018681 |
| Headache | ruxolitinib | PT | C0018681 |
| Hepatobiliary disease | ruxolitinib | LLT | C0267792 |
| Hepatobiliary disease | ruxolitinib | PT | C0267792 |
| Herpes zoster | ruxolitinib | LLT | C0019360 |
| Herpes zoster | ruxolitinib | PT | C0019360 |
| Hypercholesterolaemia | ruxolitinib | LLT | C0020443 |
| Hypercholesterolaemia | ruxolitinib | PT | C0020443 |
| Infection | ruxolitinib | LLT | C0009450 |
| Infection | ruxolitinib | PT | C0009450 |
| Infestation | ruxolitinib | PT | C1384353 |
| Infestation NOS | ruxolitinib | LLT | C0851341 |
| Kidney infection | ruxolitinib | LLT | C0021313 |
| Kidney infection | ruxolitinib | PT | C0021313 |
| Malnutrition | ruxolitinib | LLT | C0162429 |
| Malnutrition | ruxolitinib | PT | C0162429 |
| Myelosuppression | ruxolitinib | LLT | C0854467 |
| Nervous system disorder | ruxolitinib | LLT | C0027765 |
| Nervous system disorder | ruxolitinib | PT | C0027765 |
| Neutropenia | ruxolitinib | LLT | C0027947 |
| Neutropenia | ruxolitinib | PT | C0027947 |
| Night sweats | ruxolitinib | LLT | C0028081 |
| Night sweats | ruxolitinib | PT | C0028081 |
| Pancytopenia | ruxolitinib | PT | C0030312 |
| Plasma cell myeloma | ruxolitinib | LLT | C0026764 |
| Plasma cell myeloma | ruxolitinib | PT | C0026764 |
| Plasmacytoma | ruxolitinib | PT | C0032131 |
| Post procedural haemorrhage | ruxolitinib | LLT | C0919874 |
| Post procedural haemorrhage | ruxolitinib | PT | C0919874 |
| Prostate cancer | ruxolitinib | LLT | C0376358 |
| Prostate cancer | ruxolitinib | PT | C0376358 |
| Pruritus | ruxolitinib | LLT | C0033774 |
| Pruritus | ruxolitinib | PT | C0033774 |
| Skin disorder | ruxolitinib | PT | C0037274 |
| Thrombocytopenia | ruxolitinib | LLT | C0040034 |
| Thrombocytopenia | ruxolitinib | PT | C0040034 |
| Tuberculosis | ruxolitinib | LLT | C0041296 |
| Tuberculosis | ruxolitinib | PT | C0041296 |
| Unspecified disorder of skin and subcutaneous tissue | ruxolitinib | LLT | C0178298 |
| Urinary tract infection | ruxolitinib | LLT | C0042029 |
| Urinary tract infection | ruxolitinib | PT | C0042029 |
| Urosepsis | ruxolitinib | LLT | C0149801 |
| Urosepsis | ruxolitinib | PT | C0149801 |
| Weight decreased | ruxolitinib | LLT | C0043096 |
| Weight decreased | ruxolitinib | PT | C0043096 |
| Weight increased | ruxolitinib | LLT | C0043094 |
| Weight increased | ruxolitinib | PT | C0043094 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ruxolitinib used for in pharmaceutical contexts?
Ruxolitinib (CAS 941678-49-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ruxolitinib?
Ruxolitinib has 480 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Splenomegaly, Platelet count decreased, Anaemia, Haemoglobin decreased, Second primary malignancy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ruxolitinib also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Ruxolitinib.
What clinical phase is Ruxolitinib in?
No phase 1-4 clinical development badge is rendered for Ruxolitinib because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Ruxolitinib?
Ruxolitinib has 141 bioactivity rows in this page query. Rendered target entries include Rho-associated protein kinase 2, Tyrosine-protein kinase JAK3, Tyrosine-protein kinase ABL1, Mast/stem cell growth factor receptor Kit, Serine/threonine-protein kinase B-raf.